The Economic Impact of Coronavirus on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : In-depth study on Industry Size and Analysis on…

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth Projection

The new report on the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is an extensive study on the overall prospects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in the upcoming years and the impact of the COVID-19 pandemic on the Platelet Rich Plasma and Stem Cell Alopecia Treatment . In addition, the report offers valuable insights pertaining to the supply chain challenges market players are likely to face in the upcoming months and solutions to tackle the same.

The report suggests that the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market over the considered assessment period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2640669&source=atm

The report clarifies the following doubts related to the Platelet Rich Plasma and Stem Cell Alopecia Treatment market:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2640669&source=atm

Segmentation of the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Market: Drivers and RestrainsThe research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026. This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Segment Analysis The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Regional AnalysisThe research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.Following are the segments covered by the report are:Androgenic AlopeciaCongenital AlopeciaCicatricial Or Scarring AlopeciaBy Application:HospitalDermatology ClinicOtherKey Players:The Key manufacturers that are operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market are:KerastemEclipseRegen Lab SAStemcell TechnologiesRepliCel Life SciencesHistogenGlofinn Oy.Competitive LandscapeThe analysts have provided a comprehensive analysis of the competitive landscape of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2640669&licType=S&source=atm

Vital Information Enclosed in the Report

Read the original:
The Economic Impact of Coronavirus on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : In-depth study on Industry Size and Analysis on...

World coronavirus Dispatch: Rheumatoid Arthritis Stem Cell Therapy market to witness robust revenue growth between 2018 to 2028 – Cole of Duty

The global Rheumatoid Arthritis Stem Cell Therapy market is experiencing a slowdown in trade practices amidst the growing COVID-19 (Coronavirus) pandemic. This is why, companies in the Rheumatoid Arthritis Stem Cell Therapy market are vying opportunities that serve as alternative solutions to positively capitalize on the ongoing lockdown period. This and more strategic implications enclosed in our comprehensive report on the Rheumatoid Arthritis Stem Cell Therapy market that will help you take market lead.

Assessment of the Global Rheumatoid Arthritis Stem Cell Therapy Market

The recently published market study on the global Rheumatoid Arthritis Stem Cell Therapy market by Fact.MR offers an elaborate analysis of the different market parameters that are poised to influence the overall dynamics of the Rheumatoid Arthritis Stem Cell Therapy market. Further, the study reveals that the global Rheumatoid Arthritis Stem Cell Therapy market is forecasted to grow at a CAGR of ~XX% through the forecast period (20XX-20XX) and reach a market value of ~US$ by the end of 20XX.

The presented study provides critical insights related to the future prospects of the Rheumatoid Arthritis Stem Cell Therapy market by analyzing the different segments and sub-segments of the Rheumatoid Arthritis Stem Cell Therapy market. Further, the report is divided into different sections to provide readers a clear understanding of the different aspects of the Rheumatoid Arthritis Stem Cell Therapy market.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Critical insights enclosed in the report:

Important market segments included in the report:

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

The market study addresses the following queries related to the global Rheumatoid Arthritis Stem Cell Therapy market:

Why Purchase Reports from Fact.MR?

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Read this article:
World coronavirus Dispatch: Rheumatoid Arthritis Stem Cell Therapy market to witness robust revenue growth between 2018 to 2028 - Cole of Duty

Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 – TheStreet

Courtesy of Alexander (Sasha) Poltorak, Tufts University

The killer is not the virus but the immune response.

The current pandemic is unique not just because it is caused by a new virus that puts everyone at risk, but also because the range of innate immune responses is diverse and unpredictable. In some it is strong enough to kill. In others it is relatively mild.

My research relates to innate immunity. Innate immunity is a persons inborn defense against pathogens that instruct the bodys adaptive immune system to produce antibodies against viruses. Those antibody responses can be later used for developing vaccination approaches. Working in the lab of Nobel laureate Bruce Beutler, I co-authored the paper that explained how the cells that make up the bodys innate immune system recognize pathogens, and how overreacting to them in general could be detrimental to the host. This is especially true in the COVID-19 patients who are overreacting to the virus.

I study inflammatory response and cell death, which are two principal components of the innate response. White blood cells called macrophages use a set of sensors to recognize the pathogen and produce proteins called cytokines, which trigger inflammation and recruit other cells of the innate immune system for help. In addition, macrophages instruct the adaptive immune system to learn about the pathogen and ultimately produce antibodies.

To survive within the host, successful pathogens silence the inflammatory response. They do this by blocking the ability of macrophages to release cytokines and alert the rest of the immune system. To counteract the viruss silencing, infected cells commit suicide, or cell death. Although detrimental at the cellular level, cell death is beneficial at the level of the organism because it stops proliferation of the pathogen.

For example, the pathogen that caused the bubonic plague, which killed half of the human population in Europe between 1347 and 1351, was able to disable, or silence, peoples white blood cells and proliferate in them, ultimately causing the death of the individual. However, in rodents the infection played out differently. Just the infected macrophages of rodents died, thus limiting proliferation of the pathogen in the rodents bodies which enabled them to survive.

The silent response to plague is strikingly different from the violent response to SARS-CoV-2, the virus that causes COVID-19. This suggests that keeping the right balance of innate response is crucial for the survival of COVID-19 patients.

Heres how an overreaction from the immune system can endanger a person fighting off an infection.

Some of the proteins that trigger inflammation, named chemokines, alert other immune cells like neutrophils, which are professional microbe eaters to convene at the site of infections where they can arrive first and digest the pathogen.

Others cytokines such as interleukin 1b, interleukin 6 and tumor necrosis factor guide neutrophils from the blood vessels to the infected tissue. These cytokines can increase heartbeat, elevate body temperature, trigger blood clots that trap the pathogen and stimulate the neurons in the brain to modulate body temperature, fever, weight loss and other physiological responses that have evolved to kill the virus.

When the production of these same cytokines is uncontrolled, immunologists describe the situation as a cytokine storm. During a cytokine storm, the blood vessels widen further (vasolidation), leading to low blood pressure and widespread blood vessel injury. The storm triggers a flood of white blood cells to enter the lungs, which in turn summon more immune cells that target and kill virus-infected cells. The result of this battle is a stew of fluid and dead cells, and subsequent organ failure.

The cytokine storm is a centerpiece of the COVID-19 pathology with devastating consequences for the host.

When the cells fail to terminate the inflammatory response, production of the cytokines make macrophages hyperactive. The hyperactivated macrophages destroy the stem cells in the bone marrow, which leads to anemia. Heightened interleukin 1b results in fever and organ failure. The excessive tumor necrosis factor causes massive death of the cells lining the blood vessels, which become clotted. At some point, the storm becomes unstoppable and irreversible.

One strategy behind the treatments for COVID is, in part, based in part on breaking the vicious cycle of the cytokine storm. This can be done by using antibodies to block the primary mediators of the storm, like IL6, or its receptor, which is present on all cells of the body.

Inhibition of tumor necrosis factor can be achieved with FDA-approved antibody drugs like Remicade or Humira or with a soluble receptor such as Enbrel (originally developed by Bruce Beutler) which binds to tumor necrosis factor and prevents it from triggering inflammation. The global market for tumor necrosis factor inhibitors is US$22 billion.

Drugs that block various cytokines are now in clinical trials to test whether they are effective for stopping the deadly spiral in COVID-19.

[Get facts about coronavirus and the latest research. Sign up for The Conversations newsletter.]

Alexander (Sasha) Poltorak, Professor of Immunology, Tufts University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Link:
Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - TheStreet

Animal Stem Cell Therapy Market: Overview, Opportunities, Analysis of Features, Benefits, Manufacturing Cost and Forecast To 2025 – Cole of Duty

The Global Animal Stem Cell Therapy Market report provides information by Key Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast.

Initially, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Animal Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Complete Report on Animal Stem Cell Therapy market spread across 144 pages and Top companies. Get SAMPLE at https://www.insidemarketreports.com/sample-request/10/334201/Animal-Stem-Cell-Therapy

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Global Animal Stem Cell Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

The Top players are MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics,.

The Report covers following things

The report introduces Animal Stem Cell Therapy basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Animal Stem Cell Therapy market for the coming few years have also been included in the report.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading Animal Stem Cell Therapy Market players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

The Animal Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

Purchase a copy of this report at https://www.insidemarketreports.com/buy-now/10/334201/Animal-Stem-Cell-Therapy/single

Purchase this Report now by availing up to 40% Discount and free consultation.Offer is valid for May 2020 only.

Table of Contents

1 Animal Stem Cell Therapy Market Overview

2 Global Animal Stem Cell Therapy Market Competition by Manufacturers

3 Global Animal Stem Cell Therapy Capacity, Production, Revenue (Value) by Region)

4 Global Animal Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region

5 Global Animal Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

6 Global Animal Stem Cell Therapy Market Analysis by Application

7 Global Animal Stem Cell Therapy Manufacturers Profiles/Analysis

8 Animal Stem Cell Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Animal Stem Cell Therapy Market Forecast

13 Research Findings and Conclusion

14 Appendix

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Go here to read the rest:
Animal Stem Cell Therapy Market: Overview, Opportunities, Analysis of Features, Benefits, Manufacturing Cost and Forecast To 2025 - Cole of Duty

In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with…

Abstract

Increasing occurrence of moderate to severe intrauterine adhesion (IUA) is seriously affecting the quality of human life. The aim of the study was to establish IUA models in nonhuman primates and to explore the dual repair effects of human umbilical cordderived mesenchymal stem cells (huMSCs) loaded on autocrosslinked hyaluronic acid gel (HA-GEL) on endometrial damage and adhesion. Here, we recorded the menstrual cycle data in detail with uterine cavities observed and endometrial tissues detected after intervention, and the thicker endometria, decreased amount of fibrotic formation, increased number of endometrium glands, etc., suggested that both HA-GEL and huMSC/HA-GEL complexes could partially repair IUA caused by mechanical injury, but huMSC/HA-GEL complex transplantation had notable dual repair effects: a reliable antiadhesion property and the promotion of endometrial regeneration.

Intrauterine adhesion (IUA), known as Asherman syndrome, is described as the partial or complete binding of the uterine cavity due to the buildup of scar tissue formation in the upper functional layer, resulting from endometrial damage to the lower basal layer (1). Repeated intrauterine operations, such as dilatation and curettage (D&C) and hysteroscopy, are the main cause of the common prevalence of IUA, with approximately 45% of moderate-to-severe cases occurring in these circumstances (2). Severe endometrium dysfunction will cause women within reproductive age to have this reproductive disadvantage, which was once considered a terminal disease that caused infertility (3, 4).

Therefore, the vital aim for IUA treatment is to re-establish the uterine cavity and restore endometrial function. The current and standard operation method for IUA is hysteroscopic transcervical resection of adhesion (TCRA), while the preferred alternative involves the combined application of various adjuvant therapies, including physical barriers (contraceptive device, intrauterine balloon device, Foley balloon, etc.) for postoperative adhesion and estrogen therapy and amnion graft for endometrial regeneration (58). Although there is a certain therapeutic efficacy of these antiadhesion strategies, there are some disadvantages and shortcomings to the strategies that cannot be ignored, such as resistance to secondary surgery, limited area of isolation, induction of intrauterine inflammatory response, and difficulty in endometrial regeneration (9). Further, the high recurrence rate of postoperative adhesion and the low clinical pregnancy rate are still a focus and are universally recognized as a problem for patients with severe IUAs (4, 10).

Autocrosslinked hyaluronic acid gel (HA-GEL), another promising physical barrier with natural mix of extracellular matrix and synovial fluid, has been approved by China Food & Drug Administration (CFDA) as a medical device for clinical practice after hysteroscopic adhesiolysis to achieve improvement in histocompatibility and viscosity, and the American Association of Gynecologic Laparoscopists has reported the effectiveness of HA-GEL in the prevention of IUAs in 2017 (11). The application of HA-GEL in uterine cavity treatment has its own advantages of few degradations by product retention following the outflow of menstrual blood (11, 12). Compared to the previously used biomaterials, HA-GEL has a prolonged absorption time (as long as 7 to 14 days), the expansion characteristics of which can continuously isolate the postoperative uterine cavity to resist adhesion recurrence, and its other material properties can regulate the inflammatory response and repair endometrial injuries. Related experimental and clinical studies have suggested that HA-GEL is effective in the prevention of postoperative adhesion, and when combined application with a TCRA operation, it showed increases (~58.5%) in the effective rate of postoperative antiadhesion and decreases (~66.1%) in the postoperative recurrence rate (13). However, for severe IUA with a seriously injured basal layer and a loss of functional endometrium, endometrial regeneration remains an enormous challenge owing to the limited efficacy of current interventions.

Recently, stem cellbased therapy has emerged as a promising and exciting method of tissue regeneration (1416). Human umbilical cordderived mesenchymal stem cells (huMSCs) originate from the embryonic mesoderm and have the potential for multipotent differentiation; they have been regarded as a promising and extensive source for cell-based therapies due to their easy collection from discarded umbilical cords and their low immunogenicity. Some studies have shown the potential of huMSCs to repair damaged tissue (1720), and the feasibility of stem cells in restoring the endometrial structure and function has also been verified by additional clinical and experimental studies (2124). In this study, we used rhesus monkeys to construct a previously unidentified animal model of IUA and aimed to develop a complex of huMSCs loaded on HA-GEL to increase the local perseverance and activity of the stem cells and to improve the poor prognosis with the following dual functions: preventing postoperative adhesion with biomaterials and repairing the full layer of uterine wall. We also aimed to analyze the related repair or endometrial injuries, to study the motivation behind endometrial regeneration, and to explore the underlying mechanisms.

huMSCs [passage 3 (P3) to P9] had an appearance that was similar to typical spindle-shaped fibroblast-like cells, and they were arranged closely with vortex-like growth (fig. S1A1). The positive cells that were expanded in the enriching culture were successfully induced to become osteoblasts with bone matrix formation and adipocytes with lipid droplet formation (fig. S1A2 and A3). In addition, fluorescence-activated cell sorting (FACS) showed that the targeted cells expressed CD44 (99.40%), CD73 (99.56%), CD90 (99.92%), and CD105 (99.80%), but not CD34, CD45, and HLA-DR (<1%; fig. S1B).

To further evaluate the safety of huMSCs on HA-GEL, FACS results preliminarily verified that there was a low parentage of apoptotic cells in the coculture group (huMSCs/HA-GEL), and there was no notable difference between the coculture group and the culture-separated group (huMSCs) (fig. S2, A to C). In addition, the live-dead cell staining result we obtained before was added, and the result showed a small number of dead cells in both the huMSCs/HA-GEL and huMSCs groups, without significant difference compared with that in the culture-separated group (huMSCs) (fig. S2, D and E).

Two months after endometrial intervention by uterine D&C, all six monkeys stopped menstruating; smaller uterine cavities and pale and uneven endometrial surfaces were observed, which had an adhesive zone full of endometrial cavity fluid. Thinner endometrial tissue was detected and observed under Doppler ultrasound scanning with discontinuous endometria and strong echo (Fig. 1A), and the endometrial thickness (1.9833 0.4298 mm) after mechanical injury showed significant differences when compared with the thickness (4.0333 0.5185 mm) before intervention (P < 0.01, n = 6; Fig. 1B and table S1). Changes in the structure of the endometrial tissues were assessed by hematoxylin and eosin (H&E) staining. Two months after mechanical injury, the endometrium was disorganized and had few or no glands (Fig. 1C). Endometrial gland numbers decreased markedly compared with those of the premechanical injury (0.6839 0.8608 versus 6.8576 2.6901 per unit area, respectively) (P < 0.001, n = 6; Fig. 1D and table S1). Similarly, to further evaluate the degree of fibrosis, Masson staining was performed at 2 months after mechanical injury (Fig. 1E). Increased fibrotic area ratios were detected and were analyzed quantitatively; more collagen deposition was observed at 2 months after mechanical injury compared with that of the premechanical injury (0.6557 0.6359% versus 0.0716 0.0942%) (P < 0.05, n = 6; Fig. 1F and table S1).

(A) Detection of Doppler ultrasound. A1: Representative image of endometrial thickness for pre-D&C; A2: Representative image of endometrial thickness at 2 months post-D&C (red arrow, the endometrium echo; blue area, the largest cross section of endometrium). (B) Comparisons of endometrial thickness for pre- or post-D&C. (C) H&E staining of endometria for pre-D&C (C1, C3, and C5) and post-D&C (C2, C4, and C6); 10401, 10403, and 10406, respectively; see table S3 for details. Inserted overview pictures are of lower magnification; black squares are highly magnified regions. (D) Masson staining of endometria for pre-D&C (D1, D3, and D5) and post-D&C (D2, D4, and D6); 10401, 10403, and 10406, respectively; see table S3 for details. Inserted overview pictures are of lower magnification; black squares are highly magnified regions. (E) Comparisons of endometrial gland numbers per unit area for pre- or post-D&C. (F) Comparisons of fibrotic area ratios for pre- or post-D&C. *P < 0.05, **P < 0.01, and ***P < 0.001 versus the pre-D&C group, and the results shown are the mean SEM of three technical replicates from each animal.

Two months after the huMSCs/HA-GEL complex was transplanted into the uterine cavity, menstruation resumed cycling in all monkeys, and there were significantly more endometrial gland numbers (4.9662 1.4935, per unit area) than there were (3.6320 1.0060, per unit area) after HA-GEL transplantation alone (P < 0.01; Fig. 2, A and B, and table S2). Moreover, the huMSCs/HA-GEL transplantation group showed marked decreases in fibrotic areas (5.5955 3.6572%) compared with that of the HA-GEL transplantation group (14.2131 13.7193%) (P < 0.01; Fig. 2, C and D, and table S2).

(A) Endometrial H&E staining at 2 months after HA-GEL transplantation (A1, A3, and A4 correspond to 10401, 10403, and 10404, respectively) and huMSCs/HA-GEL transplantation (A2, A5, and A6 correspond to 10402, 10405, and 10406, respectively); 10401 to 10406, see table S3 for details. (B) Endometrial Masson staining at 2 months after HA-GEL transplantation (B1, B3, and B4 correspond to 10401, 10403, and 10404, respectively) and huMSCs/HA-GEL transplantation (B2, B5, and B6 correspond to 10402, 10405, and 10406, respectively); 10401 to 10406, see table S3 for details. (C) Comparisons of endometrial gland numbers per unit area between the HA-GEL transplantation group and the huMSC/HA-GEL transplantation group. (D) Comparisons of fibrotic area ratios between the HA-GEL transplantation group and the huMSCs/HA-GEL transplantation group. ##P < 0.01 versus HA-GEL transplantation group, and the results shown are the mean SEM of three technical replicates from each animal.

Abdominal surgeries were carried out, and three normal uterine cavities were exposed and revealed a thicker endometrium without an adhesive zone and endometrial cavity fluid in the huMSCs/HA-GEL transplantation group, whereas three uterine cavities in the HA-GEL transplantation group were still found to be abnormal with a mild to moderate amount of adhesion and a thinner rough endometrium (Fig. 3A). In addition, the smooth and thicker endometrial tissue with a third-line echo was also revealed and verified by ultrasound examination in the huMSCs/HA-GEL transplantation group (Fig. 3B), and the endometrial thickness (4.2667 0.5558 mm) was significantly different compared with that (1.0667 0.6650 mm) in the HA-GEL transplantation group (P < 0.01; Fig. 3C and table S2). Furthermore, the ultrastructure of the endometrium in the huMSCs/HA-GEL transplantation group showed short and sparse microvilli on the surface of epithelial cells, mucinous secretions in the glandular cavity with orderly arranged cells, tight intercellular junctions, and obvious edema of stroma, but the endometrial ends were uneven and the cellular edges had a frayed morphology. Further, loose connections between cells were observed in the HA-GEL transplantation group (Fig. 3D).

(A) Representative images of uterine cavities in the HA-GEL transplantation and huMSCs/HA-GEL transplantation groups (the dotted area and the red arrow mark the endometrial area). (B) Representative images of endometrial thickness for ultrasound detection in the HA-GEL transplantation and huMSCs/HA-GEL transplantation groups (the red arrow marks the endometrial echo; the blue area marks the largest cross section of the endometrium). (C) Comparisons of endometrial thickness between the HA-GEL transplantation group and the huMSCs/HA-GEL transplantation group. (D) Representative images of ultrastructural changes in the HA-GEL transplantation and huMSCs/HA-GEL transplantation groups (the left panel shows the surface of epithelial cells; the right panel shows the intercellular changes). ##P < 0.01 versus 2 months postHA-GEL, and the results shown are the mean SEM of three technical replicates from each animal. Photos provided by Lingjuan Wang and Chengliang Xiong (Institute of Reproductive Health, Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology).

By systematic and comprehensive comparison of endometrial tissues before surgery, increased gland numbers were found both in the HA-GEL transplantation group (3.63 1.01 versus 0.68 0.86, respectively, per unit area; P < 0.001) and in the huMSCs/HA-GEL transplantation group (4.97 1.49 versus 0.68 0.86, respectively, per unit area; P < 0.001). The gland numbers were approaching normal levels (6.86 2.69, per unit area; pre-D&C) 2 months after huMSCs/HA-GEL transplantation (Fig. 4A and table S3). Conversely, the Masson staining showed an increasing degree of fibrotic aggravation 2 months after HA-GEL transplantation (14.21 13.72% versus 0.66 0.64%; P < 0.05), but there was only a slight increase in fibrosis and some relief of aggravation after transplantation of the huMSCs/HA-GEL complex (5.60 3.66 versus 0.66 0.64; P < 0.01) (Fig. 4B and table S3). There was no significant difference in endometrial thickness or after mechanical injury (1.07 0.67 versus 1.98 0.41 mm) 2 months after HA-GEL transplantation compared with that of the HA-GEL transplantation, while the endometrial thickness was notably increased after transplantation of the huMSCs/HA-GEL complex (4.27 0.56 versus 1.98 0.41 mm; P < 0.01) that was similar to the normal levels observed before mechanical injury of the endometria (4.03 0.52 mm; pre-D&C) (Fig. 4C and table S3).

(A) Comparisons of endometrial gland numbers per unit area. (B) Comparisons of ratios of fibrotic area (%). (C) Comparisons of endometrial thickness (mm). *P < 0.05, **P < 0.01, and ***P < 0.001, all versus pre-D&C; ###P < 0.001 versus pre-D&C; #P < 0.05, ##P < 0.01, and ###P < 0.001, all versus 2 months post-D&C; ##P < 0.01 versus 2 months postHA-GEL, and the results shown are the mean SEM of three technical replicates from each animal.

The probe Vysis SRY Probe LSI SRY Spectrum Orange/Vysis CEP X Spectrum Green was used to mark huMSCs by a fluorescence in situ hybridization (FISH) technique. However, it was unclear if there was homology of probe sequences for the Yp11.3 region [sex-determining region Y (SRY), associated probe sequence] and DXZ1 (Xp11.1-Xq11.1) (CEP X, associated probe sequence) between human and rhesus monkeys. By directly extracting DNA from huMSCs (containing XY chromosome) and the spleens of rhesus monkeys, it was verified that the two probe sequences did not share homology between human and rhesus monkey (fig. S3). Then, human endometrial tissue was obtained as a positive control group (Fig. 5A), and one of the three endometria in the HA-GEL transplantation group was randomly selected as a negative control (Fig. 5B). FISH detection showed the absence of a positive signal (green/orange double signal or green signal) in the endometria 2 months after huMSCs/HA-GEL transplantation (Fig. 5, C to E), suggesting that huMSCs failed to locate to the endometrium after transplantation into the uterine cavity.

(A) Positive control, human endometrium (containing XX chromosomes); the red arrow indicates the green signal for Vysis CEP X (DXZ1). (B) Endometrial localization of huMSCs in the HA-GEL transplantation group (negative control). (C to E) Distribution of huMSCs in endometria 2 months after huMSCs/HA-GEL co-transplantation. Double/single-labeled staining (orange/green signal or just green signal) cells were defined as huMSCs. For details on 10402, 10405, and 10406, see table S3. Inserted overview pictures show a lower magnification.

Furthermore, potential cytokines secreted by huMSCs were further detected in the endometria by immunofluorescence staining, and as expected, increased positive expression was found in the endometria of the huMSCs/HA-GEL transplantation group; there were significant differences in insulin-like growth factor (IGF-1), epidermal growth factor (EGF), and brain-derived neurotrophic factor (BDNF) between the two transplanted groups (P < 0.05), but there were no significant differences in vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) (Fig. 6, A and B). In addition, when compared with the HA-GEL transplantation group, the expression levels of proinflammatory cytokines [interferon- (IFN-)] were significantly decreased in the huMSCs/HA-GEL transplantation group (P < 0.01, Fig. 6C1), and significantly up-regulated expression was found for the anti-inflammatory cytokine [interleukin 4 (IL-4)] (P < 0.01, Fig. 6C2), as well as related cytokines that promote cell proliferation and tissue repair (IGF-1 and EGF) (P < 0.001, P < 0.05, respectively; Fig. 6, C3 and C4).

(A) The expression and localization of the potential cytokines secreted by huMSCs in the HA-GEL transplantation group and the huMSCs/HA-GEL transplantation group; inserted overview pictures show a lower magnification. (B) The optical density (OD) value of IGF-1, EGF, BDNF, VEGF, and HGF 2 months after HA-GEL transplantation or huMSCs/HA-GEL co-transplantation. (C1) Comparison of IFN- mRNA expression between the HA-GEL transplantation group and the huMSC/HA-GEL transplantation group. (C2) Comparison of IL-4 mRNA expression between the HA-GEL transplantation group and the huMSC/HA-GEL transplantation group. (C3) Comparison of IGF-1 mRNA expression between the HA-GEL transplantation group and the huMSC/HA-GEL transplantation group. (C4) Comparison of EGF mRNA expression between the HA-GEL transplantation group and the huMSC/HA-GEL transplantation group. *P < 0.05, **P < 0.01, and ***P < 0.001 versus 2 months postHA-GEL; the results shown are the mean SEM of three technical replicates from each animal.

At present, according to relevant reports, approximately 2.8 to 45.5% of women with impaired fertility suffer from IUA, and more than 90% of cases occur after pregnancy-related D&C (25). In this study, an IUA model was successfully established with an invasive surgery in nonhuman primates (rhesus monkeys), which have a genetic background, endocrine system, menstrual cycle, and anatomical structure that are similar to humans (26). This model allowed us to further explore new approaches for the intervention and treatment of adhesion, especially the thin endometrium caused by endometrial injury.

In the primate experiments, 6- to 7-year-old rhesus monkeys (reproductive age) were identified as the ideal subjects for establishing IUA models; they had regular menstrual cycles of approximately 21 to 30 days, which was observed and recorded in succession for the 2 months before mechanical injury. We developed the first model of endometrial injury in rhesus monkeys by open abdominal surgery; we verified the successful establishment by visualizing the hard and narrow cervix and confirmed that D&C could ultimately lead to severe IUA, which was characterized by severe endometrial fibrosis, loss of normal endometrial glands, paper-thin and discontinuous endometria, full of adhesive zone and endometrial cavity fluid, as well as amenorrhea, as noted by the American Fertility Society scoring method (27).

This study explored the effect of transplantation huMSCs combined with HA-GEL on intrauterine reconstruction and endometrial regeneration in an IUA model. In our study, when compared with the control group (transplantation of only HA-GEL), the effects of the group with huMSCs were confirmed by Doppler ultrasonic scanning, histological inspection, and ultrastructure detection 2 months after transplantation. In the experimental group, the injured endometrial tissue presented with a thicker endometrium, an increased number of endometrial glands, a decreased fibrotic area, and typical changes in the secretory phase, showing how the positive huMSCs acted upon endometrial repair and regeneration through secreting cytokines and growth factors (16); further, the HA-GEL acted as a physical barrier to severe adhesion and provided an ideal physical support for the attachment of huMSCs to prevent their rapid outflow from uterine cavity.

Specifically, in the control group (HA-GEL transplanted alone), subjects did not recover menstruation and normal uterine cavity. However, recovery of menstruation, the appearance of a normal uterine cavity, and normal cycling were observed in the other three rhesus monkeys 2 months after huMSCs/HA-GEL co-transplantation, suggesting the great effect of the huMSCs/HA-GEL complex on the reconstruction of the uterine cavity and on the blocking of adhesion. Meanwhile, we also found that HA-GEL transplantation could increase the number of endometrial glands, but it played no effective role in endometrial thickness, which was important because it was less effective than the huMSCs/HA-GEL complex. This amelioration of the damage to the endometria resulted in nearly normal levels and suggested the re-emergence of endometrial repair and regeneration after huMSCs/HA-GEL co-transplantation. In addition, the degree of fibrosis in the damaged endometria was found to be increasingly worse 2 months after transplantation despite HA-GEL or huMSCs/HA-GEL intervention, and it remained unclear whether HA-GEL had an effect on resisting fibrogenesis because of the small sample size of rhesus monkeys. Obviously, huMSCs/HA-GEL intervention relieved the worse aspects of fibrogenesis, suggesting a better outcome and potential effect on the reconstruction of abnormal tissue.

Then, it was unclear what the underlying mechanism of endometrial reconstruction was. Transplanted huMSCs were tracked in endometria, and the result showed no obvious labeled signal in endometrial tissue at 2 months after huMSCs/HA-GEL complex transplantation, which was contrary to a previous report (28, 29). To explain these conflicting results, three possibilities were proposed: (i) missed target area due to random sampling, (ii) completely eliminated following the outflow of menstrual blood, and (iii) huMSC apoptosis and depletion. However, the last two assumptions were preferred for the reason of multipoint sampling and continuous paraffin section, and if the endometrial tissues were obtained at 1 week or 2 weeks after huMSCs/HA transplantation, we might get different results owing to the similar menstrual cycles to human and different physiological function from animal models such as mice and rabbits. Alternatively, some cytokines and growth factors related to huMSCs were detected, and the results showed that huMSCs/HA-GEL complex transplantation could obviously increase the expression of IGF-1, EGF, BDNF, and so on compared to that of the control group (HA-GEL transplanted alone). Growth factors and their related peptides were deemed to mediate and regulate hormones working on target tissues through autocrine or paracrine function, and some growth factors, the endocrine basis of endometrium recycling including transforming growth factor, EGF, IGF, fibroblast growth factor, etc., were reported to regulate the differentiation and proliferation of endometrial cells (30). EGF, present in stromal and epithelial cells of the endometrium, could regulate endometrial proliferation, gland secretion, and decidual transformation (31). IGF played important roles in endometrial physiology and could regulate the cell cycle and promoted the proliferation of endometrial epithelial cells after the activation of estrogen (32, 33). Moreover, some reports showed the key role of BDNF in the regulation of endometrial cell proliferation by the downstream signal transducer and activator of transcription 3 signaling pathway and participating in the damage repair of endometrium (34, 35). Furthermore, considering the effect of huMSCs on uncontrolled fibrogenesis resulting from inflammatory activity and endometrial cell proliferation, anti-inflammatory cytokines (IL-4) were observed to be up-regulated, and proinflammatory cytokines (IFN-) were down-regulated; further, related cytokines that promote cell proliferation and tissue repair were up-regulated, such as IGF-1 and EGF, suggesting that excessive fiber formation could be inhibited by anti-inflammatory effects due to the advantageous microenvironment constructed by abundant huMSCs in the uterine cavity. VEGF, as the most important vascular growth factor, could be stimulated by ischemia and hypoxia in the endometrial layer after endometrial injury and played an important role in the early stage of endometrial repair and proliferation; during the time, angiogenesis could be promoted rapidly, but no effects were shown once the neovascularization was over (3639). We speculated that no difference found in VEGF expression might be related to the samples extracted from the endometrium during the secretory phase, a plateau stage of vascular repair and VEGF secretion in the endometrial basal layer. Overall, all of these results further verified the important role of huMSCs in damage repair by secreting a series of paracrine factors, such as anti-inflammatory factors, growth factors, and cytokines, related to constructing the microenvironment with properties such as anti-inflammatory, promoting repair, maintaining cell function, angiogenesis, etc., which was consistent with the previous report (40).

In conclusion, this study showed that both HA-GEL and huMSC/HA-GEL complexes could partially repair severe IUA caused by mechanical injury, but huMSC/HA-GEL complex transplantation indicated significant advantages in the dual repair effects of antiadhesive property and promotion of endometrial regeneration. By constructing a complex of huMSCs/HA-GEL with a biomaterial to prevent adhesion and allow stem cells to act at the appropriate site of repair of the endometrium, we have provided a method for solving a problem for patients with moderate to severe IUA and thin endometria caused by IUA. We hope that this novel strategy using the huMSCs/HA-GEL complex will be offered as a basic clinical research strategy in the future, and it might be a potential valuable treatment for gel loaded with cytokines to repair moderate to severe IUA.

The basic information for the six rhesus monkeys used in this study is shown in table S4. They were bred and supplied by Fujian Experiment Center of Nonhuman Primate for Family Planning, where they were maintained the clean-class animal feeding standards. We used these rhesus monkeys in the study following the outlined steps of the flowchart (fig. S4) from 17 September 2018 to 16 March 2019 with regular menstrual cycle observed (26). All experiments were conducted in accordance with the National Research Councils Guideline for the Care and Use of Laboratory Animals and approved by the Ethics Committee of the Center of Reproductive Medicine of Tongji Medical College of Huazhong University of Science and Technology in China.

The six rhesus monkeys were chosen for IUA models following mechanical injury, and intraperitoneal surgery was the proper choice for curettage in view of the special structure of the vagina and the cervix, which are characterized by hardness, toughness, a small aperture, and a long cervix. All monkeys were provided general anesthesia with an appropriate dose of ketamine by intramuscular injection, and then a mid-abdominal longitudinal incision was made to expose the uterus. A vertical incision (~0.5 cm) was made in the lower uterine segment. A small curettage spoon was used to deeply scrape the uterine walls until they became rough and pale, and the collected endometrial tissues were stored at 80C. Subsequently, the uterine and abdominal incisions were closed by continuous stitching with 6-0 Vicryl sutures and 3-0 silk absorbable sutures, respectively. After the operation, antibiotics were used to prevent infection, and observation on the first day after the operation showed that these rhesus monkeys were in good condition.

huMSCs were kindly provided by the Stem Cell Laboratory of the Center of Reproductive Medicine (Tongji Medical College, Huazhong University of Science and Technology, China). Frozen huMSCs between P3 and P9 were freshly seeded in 10-cm culture dishes (1 106 cells per dish) in Iscoves modified Dulbeccos medium (IMDM, Genom, China) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco, USA), penicillin (100 U/ml), and streptomycin (100 mg/ml; Gibco, USA). Briefly, the phenotypes of huMSCs were specifically identified by FACS, and the osteogenic and adipogenic capacities of the mesenchymal stem cells were assessed with a MesenCult Osteogenic Stimulatory Kit (STEMCELL Technologies Inc., Canada) and a MesenCult Adipogenic Differentiation Kit (STEMCELL Technologies Inc., Canada). P3 to P9 were used for the experiments.

To further evaluate the safety of huMSCs on HA-GEL, we mixed huMSCs (1 105 to 2 105 per well) and 300 l of HA-GEL [Con., 5 mg/ml; Bioregen, Co., Ltd., China, approved by CFDA as a medical device (no. 20153641542)] evenly with sterile syringes in 24-well plates and then added IMDM (Genom, China), including 10% (v/v) FBS (Gibco, USA), penicillin (100 U/ml), and streptomycin (100 mg/ml) (Gibco, USA). After co-culture for 48 hours, 0.8% collagenase type I supplemented with appropriate hyaluronidase was used to digest HA-GEL and release huMSCs, and FACS was chosen for the detection of cell apoptosis index in the coculture group (huMSCs/HA-GEL) and the culture-separated group (huMSCs), as well as live-dead cell detection with Live-Dead Cytotoxicity Assay Kit (MesGen Biotechnology, Shanghai).

Briefly, 50 l of huMSCs (1 107 to 2 107 cells) were injected into 200 l of HA-GEL (Bioregen, Co., Ltd. China), and then they were immediately transplanted into the uterine cavity through the open abdominal cavity. At the same time, the uterine cavity in the negative control group was injected into 200 l of HA-GEL following the same procedure that was used for the huMSC/HA-GEL transplantation group. All operations were performed under sterile conditions.

The endometrial thickness (before mechanical injury or after surgery for 2 months) was measured by an abdominal two-dimensional ultrasound system (Medison SA-600 Ultrasound System, Korea) with 3.5-MHz pulse repetition frequency to evaluate the damage to the endometrium and the endometrial regeneration.

The scraped pieces of endometrium were fixed in 4% paraformaldehyde for 24 hours and then embedded in paraffin. Serial paraffin-embedded sections (4 m) were obtained, sequentially dewaxed in xylene I and xylene II for 20 min each, and rehydrated in a series of ethanol solutions with a decreasing concentration (100% for 10 min, 100% for 10 min, 95% for 5 min, 90% for 5 min, 80% for 5 min, and 70% for 5 min). Then, the sections were rinsed in distilled water (three times, 5 min each). The sections were stained with an H&E solution (Servicebio, China) according to the manufacturers instructions. After staining, endometrial morphologic features were observed, and the number of uterine glands per unit area was counted according to five randomly selected high-power fields of each slide.

The 4-m paraffin sections of endometrium were dewaxed and rehydrated as described above and then were immersed in Masson A solution (Servicebio, China) overnight, which was followed by a brief wash under running water. Then, the sections were stained in a mixed solution of Masson A and Masson B (1:1, Servicebio, China) for 1 min, washed under running water, and placed in 1% hydrochloric acid alcohol for 10 s before they were washed again. Subsequently, sections were immersed in Masson D solution (Servicebio, China) for 6 min and then were stained in Masson E solution (Servicebio, China) for 1 min. The solution was then slightly drained, and the sections were placed directly in Masson F solution (Servicebio, China) for 2 to 30 s, and then they were rinsed in 1% glacial acetic acid for differentiation of the signals. Last, the sections were dehydrated in absolute ethyl alcohol, clarified in xylene for 5 min, and sealed in Permount Mounting Medium (Sinopharm Chemical Reagent Co., Ltd., China). Endometrial fibrosis was assessed according to five random fields on each slide, and the fibrotic area ratios were calculated using Image-Pro Plus software (version 6.0).

The total DNA samples were extracted from spleen tissue of rhesus monkeys and huMSCs carrying XY or XX chromosomes with a TIANamp Genomic DNA Kit (Tiangen Biotech Co., Ltd., Beijing). mRNA samples were extracted from endometrial tissue, and cDNA was synthesized with a RevertAid First Strand cDNA Synthesis Kit (Thermo, USA). Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the specific expression of the DXZ1 gene on the X chromosome, SRY on the Y chromosome, and IFN-, IL-4, IGF-1, and EGF using StepOne and StepOnePlus Real-Time PCR Systems Version 2.3. The final reaction volume of 20 l contained 10 l of Bestar qPCR MasterMix (SYBR Green) (DBI Bioscience), 4 l of DNA samples, 0.4 l of forward/reverse primer (10 M), and 5.2 l of DNA/RNase-free double-distilled water (ddH2O). Last, agarose gel electrophoresis was performed to verify the expression of DXZ1 and SRY in the spleen and huMSC tissues. In addition, primer sequences used for DXZ1 (Xp11.1-Xq11.1), SRY (Yp11.3 Region), IFN-, IL-4, IGF-1, and EGF are summarized in table S5.

FISH analysis was performed to trace huMSCs for 2 months after the huMSCs/HA-GEL complexes were transplanted into the uterine cavity. Endometrial tissue was collected and immediately fixed in 10% paraformaldehyde before paraffin embedding. A Vysis SRY Probe LSI SRY Spectrum Orange/Vysis CEP X Spectrum Green Kit (Abbott Laboratories, USA) was used to mark huMSCs in the endometrium. All paraffin sections were dewaxed, rehydrated, hybridized with the probe, and so on according to the probes instructions; a final counterstaining of 4,6-diamidino-2-phenylindole (DAPI) was added, and visualization took place with fluorescence microscopy (Nikon Eclipse Ci, Nikon DS-U3). The orange (SRY/Y chromosome) and/or green (DXZ1/X chromosome) signals were used to verify the presence or absence of huMSCs in the endometrium.

The following factors were analyzed after transplantation of the huMSCs/HA-GEL complex: trophic factors (cytokines) that are secreted by huMSCs [according to relevant reports (17)], proinflammatory cytokines, anti-inflammatory cytokines, and related cytokines that promote cell proliferation and tissue repair. After fixation with 4% paraformaldehyde, paraffin embedding, and cutting 4-m paraffin sections, the slides were immersed in xylene and rehydrated through incubation in a series of alcohol gradients. The following specific antibodies were applied to sections at 4C overnight in humidified chambers: recombinant anti-BDNF antibody (EPR1292) (ab108319, Abcam), anti-VEGF antibody (C-1: sc-7269, Santa Cruz), antiIGF-1 antibody (W18: sc-74116, Santa Cruz), anti-HGFa antibody (H-10: sc-374422, Santa Cruz), and anti-EGF antibody (F-9: sc-166779, Santa Cruz). Then, these sections were incubated with a Cy3-tagged secondary antibody for 1 hour at room temperature and were then rinsed in ddH2O three times. Counterstaining was performed with DAPI for 5 min, and the fluorescence signal was detected under a fluorescence microscope (Nikon Eclipse Ci, Nikon DS-U3).

We collected three technical replicates from each animal and repeated the experiments at least three times. The data presented as the mean SEM were analyzed with Statistical Package for the Social Sciences Statistics 17.0. The normally distributed numerical variance was assessed by a t test with homogeneity of variance, and 2 tests were used to analyze the differences between two or more rates. The percentage of positive area after H&E staining and Masson staining was measured using ImageJ 1.43u (Wayne Rasband, National Institutes of Health, USA). Statistical significance was assumed for P < 0.05.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: We acknowledge the breeding and technical assistance of Fujian Experiment Center of Nonhuman Primate for Family Planning. We thank C. Yu for the operation of uterine D&C and open abdominal surgery. We thank C. Xiong and P. Su for their invaluable contributions in critically revising the manuscript and providing guidance for important intellectual content. We thank M. Zhang, T. Chang, and S. Song for analyzing the data and collecting the samples. Funding: This work was supported by the National Natural Science Foundation of China (NSFC 81571434) and the National Key Research and Development Program of China (2017YFC1002002). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author contributions: W.X. designed the study and published this manuscript; L.W. and C.Y. performed the experiments and wrote the manuscript; M.Z., T.C., and S.S. analyzed the data and collected the samples; C.X. and P.S. provided their invaluable contributions in critically revising the manuscript and providing guidance for important intellectual content. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Link:
In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with...

UH studying use of convalescent plasma to improve health of COVID-19 patients – Crain’s Cleveland Business

University Hospitals is participating in a study to determine if plasma donated from someone who's recovered from COVID-19 can improve the health of patients battling the virus.

Because patients who've recovered from COVID-19 have antibodies in their blood that could help fight the virus, it is thought that those suffering complications from COVID-19 might improve faster if they receive plasma from the people who've recovered, according to a news release.

Headed at the Christ Hospital in Cincinnati, the study currently has three participating sites in Ohio. Being a part of the study enhances UH's ability to quickly get plasma for patients who need it, according to the release.

"UH is at the forefront of experimental treatments including remdesivir, stem cell therapy and now convalescent plasma," cardiologist Dr. Steven Filby said in a prepared statement. "Patients suffering from extreme complications of COVID-19 have hope at UH thanks to these options."

Filby is a co-investigator for the study, along with Dr. Eiran Gorodeski, an internist and cardiologist at UH Cleveland Medical Center, and Dr. Katharine Downes, a pathologist.

Symptoms of COVID-19 include fever, fatigue, dry cough, headache and more. In addition to respiratory distress, COVID-19 can affect the cardiovascular system. No FDA-approved medicine currently exists to treat or prevent COVID-19, according to the release.

To receive plasmas as part of this study, patients must be hospitalized with COVID-19 and be experiencing "serious complications," including myocardial injury, according to the release.

Blood donations will be collected from patients who are determined recovered and cleared from COVID-19 and who are found to have developed antibodies in their plasma. UH is partnering with Hoxworth Blood Center and Vitalant to provide donations for the study.

"Offering experimental COVID-19 convalescent plasma transfusion to our patients gives us another option to fight COVID-19," Downes said in a prepared statement. "UH appreciates our partnership with the blood suppliers that are crucial to making this happen."

Go here to see the original:
UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business

Newborn in Japan receives first treatment with liver STEM cells – ZME Science

A team of doctors in Japan have successfully transplanted stem liver cells into a newborn baby who required transplant, marking a world first.

This approach could be used in the future for other infants who require organ transplants but are still too young or frail to bear such an intervention, the team explains. The patient suffered from urea cycle disorder, a condition where the liver is not able to break down ammonia, a toxic compound, in the blood, but was considered too small to survive a surgical intervention.

The success of this trial demonstrates safety in the worlds first clinical trial using human ES (embryonic stem) cells for patients with liver disease, said a press release of Japans National Center for Child Health and Development (NCCHD) following the procedure according to todayonline.

At only six days old, the infant (whose sex has hot been disclosed) was too small to undergo a liver transplant, which is not considered safe for patients under 6 kilograms (13 pounds), according to the NCCHD, which usually means they have to be around three to five months old.

However, the babys condition would have been fatal until then, so the doctors had to find an alternative way of treatment.

They settled on a bridge treatment meant to manage the condition until the baby was big enough for transplant. This procedure involved injecting 190 million liver cells derived from embryonic stem cells into the blood vessels of the liver. And it worked.

They report that the baby did not see an increase in blood ammonia concentrations after the procedure and grew up to successfully complete the next treatment, namely a liver transplant from its father. The patient was discharged from the hospital six months after birth.

This course of treatment can be used for infant (and perhaps adult) patients who are also waiting for a transplant in other parts of the world. Doctors at the NCCHD note that Europe and the US have a relatively stable supply of liver cells from brain-dead donors, while Japan only has a limited quantity to work with. So they had to use ES cells, which are harvested from fertilized eggs, which has caused some controversy regarding how ethical their use is.

The NCCHD is one of only two organisations in Japan allowed to work with ES cells to develop new medical treatments. It works with fertilised eggs whose use has been approved by both donors having already completed fertility treatment, according to the institute.

The treatment so far isnt meant to replace transplants, but thats definitely an exciting possibility for the future. Transplants save lives, but they rely on donors (whose numbers are limited) and require highly specialized equipment, doctors, and medicine to be successful. We can, however, hope that in the future a simple injection may replace the transplants of today.

Original post:
Newborn in Japan receives first treatment with liver STEM cells - ZME Science

Japanese newborn to receive the worlds first liver stem cell – News Landed

Stem cell research is an advanced branch of science that hopes for promising and budding treatment in the future. It is quite complicated and controversial even for the scientist, due to the unstructured multiplication of cells. We know that the stem cells are specialized, undifferentiated precursor cells capable of self proliferation and differentiation. It can develop into any type of cell in the body, including muscle cells and even brain cells.

Usually, these stem cells are extracted from the inner cell of a blastocyst in a fertilized egg and so named Embryonic Stem cell. This process of extraction is generally tedious, and most importantly, it causes ethical issues due to embryo destruction.

Read Also: Parkinsons, diabetes, and other disease research affected by COVID-19

A six-day-old infant in Japan was suffering from urea cycle disorder in which the liver is not able to breakdown ammonia, a toxic compound, in the blood. Doctors suggested that liver transplant was not advisable for the baby considering the age. It was recommended only for babies who are about 3 to 5 months old weighing around six kilograms(13 pounds). As to find a temporary solution, Doctors at the National Center for Child Health and Development planned to attempt a bridge treatment until the baby attains a particular age. They injected 190 million liver cells, which were derived from embryonic stem cells into the blood vessels of the newborns liver.

On examining the babys blood after treatment, they didnt notice any abnormally elevated level of ammonia and this claimed to be a successful therapy for the first time in the world. The baby later underwent a liver transplant successfully from its father and was discharged after six months from the hospital. The institute said that the success of this trial demonstrates safety in the worlds first clinical trial using human ES cells for patients with liver disease.

Read Also: China supports coronavirus inquiry, but insists on waiting until containment

The research about the stem cell could be used in the upcoming days for many infants who require organ transplants in the initial stage without any intervention. These transplants rely mainly on donors because looking for the embryonic cell has been unscrupulous and unethical. Liver cells can be taken from brain dead patients and also people who are interested in donating liver cells. By this stem cell approach, we can prevent many genetic or acquired diseases and provide a long-lasting healthy life.

Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!

Source: MedicalXpress

See the rest here:
Japanese newborn to receive the worlds first liver stem cell - News Landed

First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer – Science Times

Edward Pierce, 49, an acclaimed Broadway set designer for plays like Wicked spent five weeks in a medically induced coma after contracting COVID-19 and was treated at a hospital in Teaneck, New Jersey.

His condition slowly deteriorated due to organ failure, and there seemed to be little hope, so his wife agreed to use an untested method developed by an Israeli biotechnology firm. He made history as the first American to receive placental cells in around 15 parts of his body.

According to the Daily Mail, Pierce was off a ventilator and breathing on his own just within ten days of treatment. The treatment is said to be part of the Food and Drugs Administrations' 'compassionate use.'

Pierce first thought that he had the flu, so doctors only prescribed him medicines and told him to stay home. However, his condition continued to worsen, and then he was admitted to the hospital. Four days later, he was put on a ventilator.

At one point in his stay, doctors had to restart his heart after it stopped when he pulled out his breathing tube. Pierce told The Daily Beast that he felt scared at the time because he does not want to be not in control.

He remembered that doctors asked him to count backwards from 10 and her wife told him that she loves him, and he said it back to her. That was the last thing he remembered before waking up five weeks later.

A lot has happened in those times, including him having kidney failure and needing dialysis. Luckily, he did not have to have that. His wife began thinking of what life would be like if Pierce did not make it. She would receive updates from the hospital, sometimes the news was good, sometimes it was not so good.

According to Pixie, the doctors are running out of options to save her husband. So they ask her to authorize an as-yet-untested treatment that extracts stem cells from human placenta.

Read Also: 115 Healthy Babies have Been Born from Mothers Infected with COVID-19 In India

Pluristem Therapeutics, an Israeli company who pioneered the treatment said that 75% of COVID-19 patients had been taken off the ventilator, according to The Jerusalem Post. The FDA permitted the company to offer the treatment on a case-by-case basis to patients under 'compassionate use.'

Compassionate use is the use of a new unapproved treatment for patients who are seriously ill and has not shown any improvements after every other option has been exhausted.

The proposed treatment includes using cells from the placenta or the intramuscular administration of the company's PLX-PAD, which is used for severe pneumonia caused by COVID-19 and preventing the deterioration of patients towards ARDS and sepsis.

Within ten days, Pierce was taken off a ventilator and started to breathe on his own. Gradually, doctors weaned him off of sedatives, and three days after he woke up, his breathing tubes, feeding tubes, and catheters were all removed.

Finally, on May 1, he was discharged from the hospital after nearly seven weeks of treatment. He was then sent to rehabilitation to rebuild his muscles and regain strength.

Read More: CDC Emphasized COVID-19 Not Easily Spread By Touching Surfaces or Objects

Excerpt from:
First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times

We now have a special power to kill the virus – Bangalore Mirror

Some good news on the Covid treatment front. Cytokine therapy trials, for mild and moderate symptoms in asymptomatic individuals and early-stage symptomatic Covid-19 infections, will begin from Monday. Though approvals are awaited, doctors are optimistic

Starting Monday, HCG Cancer Centre will start conducting cytokine therapy trial on humans, which can treat patients with mild to moderate Covid-19 infection. Cytokines are cell signalling molecules that activate immune response and direct movement of cells towards the infection/inflammation site. The therapy involves injecting this cocktail of chemicals into patients with compromised immune systems. Doctors expect the cytokines to activate the immune response in Covid-19 patients. At least 10 people have volunteered and pre-screening is currently going on at HCG. Dr US Vishal Rao, regional director of head and neck surgical oncology and robotic surgery, HCG Cancer Centre, explains the mechanics of the therapy.

Why cytokines? How do they help?We found that children with immature immune system recover very well from Covid-19 infection and tend to have milder symptoms; but those in the 65+ age bracket with a more mature immune system are at higher risk. A logical explanation to this could be the active thymus gland which is well developed in children in the mothers womb itself and gets active soon after birth. In the age group 65-plus, the thymus has degenerated.

Most people who are dying (due to Covid-19) are dying between the 8th and the 27th day (of the infection). This is because in the initial days the body has some reserve cells to fight the virus (innate immunity).

But by the 5th to 7th day, they need to start recruiting new people in this fight, for which they need the thymus. But in the 65+ age group, the thymus degenerates because the body says I have seen all the viruses I need to. So we went back to our labs and started finding out how to activate this immunity (active immunity).

Dr Jyothsna, who has worked with a Nobel Prize winner and has had a great experience with Rockefeller, and Dr Gururaj, a cell biologist with immense knowledge of these procedures, are working on this cytokine therapy.

How do you extract cytokines?We take 2ml of blood from healthy individuals and get a buffy coat (the froth generated when the blood is spun at a high velocity) full of thymic cells. We take the buffy coat and identify the specific thymus cells which are active in the immune system. We then simulate a virus attack on these cells in the laboratory. Due to this, the cells start secreting these special hormones called cytokines.

What next?There are four to five cytokines and one among them is the interferon. The word interferon means to interfere; so, when a cell is dying due to the virus, it releases interferons which are called messenger proteins. These messenger proteins quickly reach out to the neighbouring cells and inform them that there is an impending viral attack, so please get prepared.

When this happens, several other cells start getting ready with the anti-viral engine in their own blood cell machinery which will kill the virus, whenever it infects this cell.

So what did you create?We created a concoction of cytokines which we believe will reactivate the immune system completely when the virus is about to enter and attack (the system) and not at the terminal stage.

Who all can benefit from this therapy?It can be given to a Covid-19 patients primary contacts, or someone who is developing cough or cold (due to the infection). If you inject the cytokines, their immune system will be reactivated to such a level that when the virus attacks, their body will be prepared significantly to fight back. What we have done is given the body a special power to kill the virus.

How is it different from a vaccine?Vaccines prevent normal individuals from contracting the virus. Here we are trying to help people infected by the virus to kill the virus by reactivating the immune system. Will this therapy prevent viral infection again? We still do not know.The experiment on animals is successful. We wanted to see whether the animal was going to get a cytokine storm.

Cytokine storm? Whats that?Covid-19 patients who are terminally ill go through a storm, where the immune system becomes hyperactive. At this juncture, if interferons were to be given when the person is dying, the system is already releasing so many immune cells and the cells are fighting and there are multiple reactions happening. This is when the immune system gets frustrated. Then, these interferons which went to contact the thymus cells are getting surplus of the immunity and that is when it starts a storm.

In the second stage - a stage of severe illness we need to prepare the patient with plasma when the patient shows breathlessness and is not on a ventilator.

In the last stepwhen the person is on the ventilator we believe the mesenchymal stem cells are one of the best therapy and China has already given results and we are waiting for the approvals. They are doing it in the US too.

The rest is here:
We now have a special power to kill the virus - Bangalore Mirror